Proud to contribute to the Phase III Krascendo 1 study, presented at #ESMO2026 and published in @NEJM. Co-author @BoWangMD1 called the findings “potentially practice-changing” for patients with KRAS G12C-mutated lung cancer. https://www.scri.com/news/sarah-cannon-research-institute-showcases-85-oncology-research-presentations--at-esmo-2026-highlighting-advances-across-multiple-tumor-types2/